Page 2 - Nasdaq Cdmo News Today

Avid Bioservices (NASDAQ:CDMO – Get Free Report) had its target price lowered by investment analysts at Craig Hallum from $22.00 to $16.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Craig Hallum’s price target points to a potential upside of 244.83% from the […]

Profund Advisors LLC increased its holdings in shares of Avid Bioservices, Inc. (NASDAQ:CDMO – Free Report) by 11.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,044 shares of the biopharmaceutical company’s stock after buying an additional 4,069 shares during the quarter. […]

Yousif Capital Management LLC lessened its position in shares of Avid Bioservices, Inc. (NASDAQ:CDMO – Free Report) by 7.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,837 shares of the biopharmaceutical company’s stock after selling 2,285 shares during the quarter. Yousif Capital Management […]

Avid Bioservices, Inc. (NASDAQ:CDMO – Get Free Report) CFO Daniel R. Hart sold 2,040 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $9.20, for a total value of $18,768.00. Following the sale, the chief financial officer now owns 75,081 shares of the […]

Avid Bioservices, Inc. (NASDAQ:CDMO – Get Free Report) General Counsel Mark R. Ziebell sold 1,141 shares of the business’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $9.20, for a total value of $10,497.20. Following the sale, the general counsel now owns 60,515 shares of the […]

Avid Bioservices (NASDAQ:CDMO – Free Report) had its target price lowered by Royal Bank of Canada from $17.00 to $15.00 in a research report sent to investors on Friday morning, Marketbeat.com reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical company’s stock. Separately, Stephens decreased their target price on Avid Bioservices […]

Avid Bioservices (NASDAQ:CDMO – Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01, MarketWatch Earnings reports. Avid Bioservices had a negative net margin of 2.06% and a negative return on equity of 1.55%. The company had revenue of […]

Avid Bioservices, Inc. (NASDAQ:CDMO – Get Free Report)’s stock price reached a new 52-week low during trading on Friday after Royal Bank of Canada lowered their price target on the stock from $17.00 to $15.00. The stock traded as low as $10.08 and last traded at $10.58, with a volume of 63865 shares changing hands. […]

Kornitzer Capital Management Inc. KS grew its position in shares of Avid Bioservices, Inc. (NASDAQ:CDMO – Free Report) by 12.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 682,510 shares of the biopharmaceutical company’s stock after buying an additional 75,065 shares during the […]

Scissortail Wealth Management LLC bought a new stake in shares of Avid Bioservices, Inc. (NASDAQ:CDMO – Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,867 shares of the biopharmaceutical company’s stock, valued at approximately $304,617,000. Several other hedge funds also recently […]